Dovato Cost in 2026: What You Pay With and Without Insurance

Dovato (dolutegravir/lamivudine) is a once-daily, two-drug HIV-1 regimen with a US list price of $3,250.47 for a 30-day supply as of January 1, 2026, according to manufacturer ViiV Healthcare. Most patients pay far less. SunnyPharma tracks the published price points, copay programs, and patient-assistance pathways for Dovato so cost-burdened patients can see the full picture in one place — including the gaps that drug-discount sites tend to leave out.

Dovato cost without insurance

Without any insurance or savings program, Dovato’s cash price varies more than $1,300 between commonly cited sources. The spread is real — and it matters because cash payers often pay whatever the pharmacy rings up first, without comparing.

The reason for the spread: each source measures something slightly different. The manufacturer publishes the Wholesale Acquisition Cost (WAC), the price at which wholesalers buy from ViiV. Pharmacies mark that up to a retail “usual and customary” price, which can be $500–$1,000 higher. Discount-card networks (GoodRx, SingleCare) negotiate contracted rates with specific pharmacy chains and publish those. Whichever number a website leads with depends on its business model — not on what you’ll actually pay at the counter.

For an uninsured patient, the practical floor on a Dovato 30-day supply at a US retail pharmacy is around $2,900 with a discount card, and the practical ceiling is around $4,200 without one. Annualized, that’s $34,800 to $50,400 per year at cash prices.

Dovato cost with insurance

Dovato is on the formulary of every major commercial insurer in the United States, but where it sits in the formulary tier structure determines what you pay out of pocket. Specialty drugs are typically Tier 4 or Tier 5, meaning higher copays or coinsurance than generic or preferred-brand medications.

With commercial (employer or marketplace) insurance

The single most useful program for commercially insured patients is the ViiVConnect Savings Card. Eligible patients with commercial insurance pay an average of about $1 per fill on Dovato, compared with about $82 without the card, according to ViiV. The annual maximum benefit is $6,250. Patients with government-funded insurance (Medicare, Medicaid, TRICARE, VA) are not eligible — federal anti-kickback rules prohibit it.

With Medicare Part D

Medicare Part D plans cover Dovato, but cost depends on which coverage phase you are in (deductible, initial coverage, or catastrophic). About 80% of Medicare Dovato prescriptions cost less than $10 per month, per ViiV, but that figure includes patients receiving Extra Help (Low Income Subsidy). Patients in the deductible phase can pay $100 or more per fill. The 2026 Medicare Part D out-of-pocket cap is $2,000 annually — meaning total spending on covered drugs cannot exceed that ceiling for any beneficiary.

With Medicaid

About 88% of Medicaid patients pay $0 per Dovato prescription; the rest pay under $10, per ViiV. Medicaid coverage is automatic if you qualify for the program in your state.

Dovato patient assistance program eligibility

The ViiV Patient Assistance Program (administered through ViiVConnect) provides Dovato at no cost to qualifying patients. Eligibility, per ViiV’s published criteria:

• US resident
• No insurance coverage for Dovato, or inadequate coverage
• Household income below the program’s threshold (typically tied to Federal Poverty Level guidelines, with the exact ceiling published in the application)

Application takes 1–2 weeks to process. ViiV may issue a bridge supply during the review period if you’re at risk of running out. Apply through your prescribing clinician — the form requires a provider signature. The ViiVConnect line is 1-844-588-3288.

Medicare Part D patients who fall outside standard PAP eligibility may still qualify under specific criteria; the program will assess case by case.

ADAP coverage for Dovato

The AIDS Drug Assistance Program (ADAP), administered state-by-state under the federal Ryan White HIV/AIDS Program, covers Dovato in every US state and territory. ADAP is the safety-net program HIV.gov consistently recommends for patients without sufficient insurance. Income eligibility varies by state — most cap at 400–500% of the Federal Poverty Level — and some states have brief waiting lists.

For Medicare patients, “ADAP wrap-around” pays Part D copays, premiums, and the deductible for HIV medications, including Dovato. This pathway is invisible on most cost-comparison sites but is one of the most important coverage tools for low-income Medicare patients. Apply through your state ADAP office; NASTAD maintains a state-by-state formulary map.

If you’re not sure which program fits your situation, the SunnyPharma HIV medication access screener walks through the eligibility logic in five questions and points to the correct pathway.

Is there a generic Dovato?

No FDA-approved generic version of Dovato (dolutegravir/lamivudine fixed-dose combination) is available in the United States as of April 2026. Based on the patent landscape for the combination product, a generic is unlikely before 2031.

The two component drugs are available individually as generics. This raises a question that comes up often: can you save money by taking generic dolutegravir and generic lamivudine separately instead of brand Dovato? The math, using SingleCare’s 2024 cash-price reference points:

The savings from substituting separately don’t materialize because dolutegravir alone (Tivicay) has no FDA-approved generic in the US either. Brand Tivicay carries a list price of about $2,800 for a 30-day supply. Generic lamivudine adds roughly $580. The combined retail is in the same range as brand Dovato — and the patient now takes two pills instead of one, which can affect adherence. This substitution is sometimes used in clinical practice but rarely produces meaningful savings for a US patient paying cash.

Once a true generic dolutegravir/lamivudine combination is approved (likely after 2031), the cost picture changes substantially. Until then, the brand-name discount and assistance pathways above are the realistic levers.

Why retail prices vary so much for Dovato

The $1,300 spread between published Dovato prices isn’t a measurement error — each number reflects a different pricing layer in the US drug supply chain.

• Manufacturer list price (WAC): $3,250.47. The price ViiV publishes; what wholesalers pay.
• Pharmacy “usual and customary”: $3,500–$4,200. The marked-up price a pharmacy charges if no insurance or discount card is presented.
• Discount-card network rate: $2,900–$3,200. The pre-negotiated rate at chains contracted with GoodRx, SingleCare, Optum Perks, etc.
• Insurance-negotiated rate: Usually invisible to the patient. Health plans negotiate confidential rebates with ViiV; the patient sees only their copay.
• Patient out-of-pocket with copay card: ~$1 per fill for eligible commercially insured patients.
• Patient out-of-pocket with PAP or ADAP: $0.

The practical takeaway: never pay the price the pharmacy quotes first without checking at least one discount-card price and confirming whether you’re eligible for a copay card or assistance program. The same Dovato prescription can cost $0 or $4,200 in the same week at the same pharmacy depending on which pathway is used.

Where Dovato fits in current HIV treatment guidelines

The US Department of Health and Human Services Adult and Adolescent ARV Guidelines list dolutegravir/lamivudine (Dovato) as a recommended initial regimen for most people with HIV-1 — one of only a handful of two-drug regimens given that designation. Cost should be a planning factor, not a barrier. If Dovato is the right clinical choice but the price is the obstacle, the assistance pathways above exist precisely for that scenario.

Frequently asked questions